SQZ Biotechnologies Inkomsten in het verleden
Verleden criteriumcontroles 0/6
SQZ Biotechnologies has been growing earnings at an average annual rate of 7.8%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 44.6% per year.
Belangrijke informatie
7.8%
Groei van de winst
11.0%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.0% |
| Inkomstengroei | -44.6% |
| Rendement op eigen vermogen | -3,808.8% |
| Nettomarge | -591.1% |
| Laatste winstupdate | 30 Sep 2023 |
Recente prestatie-updates uit het verleden
Recent updates
SQZ Biotechnologies Company (NYSE:SQZ) Might Not Be As Mispriced As It Looks After Plunging 30%
Jun 26
We Think SQZ Biotechnologies (NYSE:SQZ) Needs To Drive Business Growth Carefully
Jan 05SQZ Biotechnologies GAAP EPS of -$0.77 beats by $0.06, revenue of $3.5M misses by $0.76M
Nov 09SQZ Biotech spikes as H.C. Wainwright initiates with Buy citing platform technology
Oct 20Is SQZ Biotechnologies (NYSE:SQZ) In A Good Position To Deliver On Growth Plans?
Aug 20SQZ Biotechnologies GAAP EPS of -$0.78 misses by $0.01, revenue of $3.22M misses by $0.97M
Aug 04SQZ Biotechnologies names business chief as CFO
Jul 11Time To Worry? Analysts Just Downgraded Their SQZ Biotechnologies Company (NYSE:SQZ) Outlook
May 17Here's Why We're Watching SQZ Biotechnologies' (NYSE:SQZ) Cash Burn Situation
May 02Here's Why We're Watching SQZ Biotechnologies' (NYSE:SQZ) Cash Burn Situation
Jan 11Will SQZ Biotechnologies (NYSE:SQZ) Spend Its Cash Wisely?
Jul 30Need To Know: Analysts Are Much More Bullish On SQZ Biotechnologies Company (NYSE:SQZ)
May 16Newsflash: SQZ Biotechnologies Company (NYSE:SQZ) Analysts Have Been Trimming Their Revenue Forecasts
Mar 25SQZ Biotechnologies Company (NYSE:SQZ) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 20We Think SQZ Biotechnologies (NYSE:SQZ) Can Afford To Drive Business Growth
Feb 01
Opbrengsten en kosten
Hoe SQZ Biotechnologies geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 23 | 12 | -72 | 21 | 0 |
| 30 Jun 23 | 16 | -71 | 22 | 0 |
| 31 Mar 23 | 19 | -76 | 25 | 0 |
| 31 Dec 22 | 21 | -79 | 26 | 0 |
| 30 Sep 22 | 22 | -78 | 28 | 0 |
| 30 Jun 22 | 23 | -78 | 28 | 0 |
| 31 Mar 22 | 25 | -74 | 27 | 0 |
| 31 Dec 21 | 27 | -69 | 26 | 0 |
| 30 Sep 21 | 17 | -75 | 25 | 0 |
| 30 Jun 21 | 19 | -64 | 23 | 0 |
| 31 Mar 21 | 20 | -55 | 21 | 0 |
| 31 Dec 20 | 21 | -51 | 21 | 0 |
| 30 Sep 20 | 25 | -43 | 21 | 0 |
| 30 Jun 20 | 23 | -39 | 21 | 0 |
| 31 Mar 20 | 21 | -37 | 20 | 0 |
| 31 Dec 19 | 20 | -32 | 18 | 0 |
| 31 Dec 18 | 13 | -20 | 9 | 0 |
Kwaliteitswinsten: SQZB is currently unprofitable.
Groeiende winstmarge: SQZB is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: Insufficient data to determine if SQZB's year-on-year earnings growth rate was positive over the past 5 years.
Versnelling van de groei: Unable to compare SQZB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: SQZB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: SQZB has a negative Return on Equity (-3808.77%), as it is currently unprofitable.